Price T Rowe Associates Inc Moon Lake Immunotherapeutics Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,973,830 shares of MLTX stock, worth $145 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,973,830
Previous 3,343,643
11.06%
Holding current value
$145 Million
Previous $181 Million
35.83%
% of portfolio
0.01%
Previous 0.02%
Shares
12 transactions
Others Institutions Holding MLTX
# of Institutions
161Shares Held
55.2MCall Options Held
481KPut Options Held
229K-
Bvf Inc San Francisco, CA19.8MShares$966 Million33.91% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$415 Million35.2% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$135 Million1.75% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.48MShares$72.3 Million0.01% of portfolio
-
Westfield Capital Management CO LP Boston, MA1.43MShares$70.1 Million0.29% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.81B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...